Gritstone bio, Inc. ( NASDAQ:GRTS ) just released its latest yearly results and things are looking bullish. Overall...
Gritstone bio ( NASDAQ:GRTS ) Full Year 2023 Results Key Financial Results Revenue: US$16.3m (down 18% from FY 2022...
-- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone’s personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q 2024 -- -- National Cancer Institute-led Phase 1 study evaluating Gritstone's "off-the-shelf" cancer vaccine, SLATE, combined with neoantigen cell therapy expected to begin in the coming months -- -- Gritstone incorporating GMP-grade raw materials in the manufacture of its samRNA v